Radiotherapy system receives CE mark extension

Article

A proprietary radiotherapy system (IRay, Oraya Therapeutics) used to treat exudative age-related macular degeneration (AMD) now also may be used to treat choroidal metastases following a CE mark extension.

A proprietary radiotherapy system (IRay, Oraya Therapeutics) used to treat exudative age-related macular degeneration (AMD) now also may be used to treat choroidal metastases following a CE mark extension.

“While Oraya’s primary focus remains on treating wet AMD, we continue to identify and evaluate other uses of the technology that may benefit patients and clinicians,” Oraya CEO Jim Taylor said in a statement.

More in this issue: Visual function linked to preBCVA in AMD cataract patients

The system delivers radiation to the back of the eye via a robotically positioned low-energy X-ray source. According to Oraya, the 15- to 20-minute non-invasive procedure is an alternative to surgery and related multiple treatment sessions.

The proprietary radiotherapy system received CE certification for the treatment of exudative AMD in March 2010, and the company actively began commercializing it in 2014. The radiotherapy is now available at 11 treatment centers in Germany, the UK and Switzerland, and plans are under way that would enable it to be available at an additional 11 centers.

 

In December 2014, Carl Zeiss Meditec AG and Oraya entered into a collaboration through which Carl Zeiss Meditec will fund Oraya’s growth strategy, particularly its expansion in Europe, for up to 2 years. In the US the system is considered an investigational device and is not available for purchase.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.